Lexeo Therapeutics, Common Stock Alpha and Beta Analysis
| LXEO Stock | 5.07 0.12 2.31% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Lexeo Therapeutics, Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in Lexeo Therapeutics, over a specified time horizon. Remember, high Lexeo Therapeutics,'s alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Lexeo Therapeutics,'s market risk premium analysis include:
Beta 0.24 | Alpha (0.50) | Risk 5.69 | Sharpe Ratio (0.18) | Expected Return (1.03) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Lexeo |
Lexeo Therapeutics, Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Lexeo Therapeutics, market risk premium is the additional return an investor will receive from holding Lexeo Therapeutics, long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Lexeo Therapeutics,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Lexeo Therapeutics,'s performance over market.| α | -0.5 | β | 0.24 |
Lexeo Therapeutics, expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Lexeo Therapeutics,'s Buy-and-hold return. Our buy-and-hold chart shows how Lexeo Therapeutics, performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Lexeo Therapeutics, Market Price Analysis
Market price analysis indicators help investors to evaluate how Lexeo Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Lexeo Therapeutics, shares will generate the highest return on investment. By understating and applying Lexeo Therapeutics, stock market price indicators, traders can identify Lexeo Therapeutics, position entry and exit signals to maximize returns.
Lexeo Therapeutics, Return and Market Media
The median price of Lexeo Therapeutics, for the period between Sun, Oct 20, 2024 and Sat, Jan 18, 2025 is 7.35 with a coefficient of variation of 16.99. The daily time series for the period is distributed with a sample standard deviation of 1.29, arithmetic mean of 7.57, and mean deviation of 1.02. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Lexeo Therapeutics to Present New Interim Data from Phase 12 Trial of LX1001 at the Clinical Trials on Alzheimers Disease 2024 Conference | 10/22/2024 |
2 | Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimers Dis... | 10/30/2024 |
3 | Insider Trading | 11/11/2024 |
4 | Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results | 11/13/2024 |
5 | Janus Henderson Group PLCs Strategic Acquisition in Lexeo Therapeutics Inc | 11/14/2024 |
6 | Heres Why Were Watching Lexeo Therapeutics Cash Burn Situation | 11/20/2024 |
7 | Acquisition by Cholmondeley Paula H of 15000 shares of Lexeo Therapeutics, at 6.9901 subject to Rule 16b-3 | 11/25/2024 |
8 | Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024 | 12/02/2024 |
9 | Lexeo Therapeutics names Kyle Rasbach as CFO | 12/19/2024 |
10 | Acquisition by Omega Fund Vi, L.p. of 287213 shares of Lexeo Therapeutics, subject to Rule 16b-3 | 01/03/2025 |
11 | Acquisition by Adler Eric of 43750 shares of Lexeo Therapeutics, subject to Rule 16b-3 | 01/07/2025 |
About Lexeo Therapeutics, Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Lexeo or other stocks. Alpha measures the amount that position in Lexeo Therapeutics, has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 5.58 | 7.21 | 8.29 | 7.88 | Net Debt To EBITDA | 1.1 | 1.65 | 1.89 | 3.08 |
Lexeo Therapeutics, Upcoming Company Events
As portrayed in its financial statements, the presentation of Lexeo Therapeutics,'s financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lexeo Therapeutics,'s leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Lexeo Therapeutics,'s public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Lexeo Therapeutics,. Please utilize our Beneish M Score to check the likelihood of Lexeo Therapeutics,'s management manipulating its earnings.
| 4th of November 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of November 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Lexeo Therapeutics,
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Lexeo Therapeutics, Backtesting, Lexeo Therapeutics, Valuation, Lexeo Therapeutics, Correlation, Lexeo Therapeutics, Hype Analysis, Lexeo Therapeutics, Volatility, Lexeo Therapeutics, History and analyze Lexeo Therapeutics, Performance. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Lexeo Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.